WO2016198579A1 - Système d'épuration du sang reposant sur l'hémoconcentration - Google Patents

Système d'épuration du sang reposant sur l'hémoconcentration Download PDF

Info

Publication number
WO2016198579A1
WO2016198579A1 PCT/EP2016/063265 EP2016063265W WO2016198579A1 WO 2016198579 A1 WO2016198579 A1 WO 2016198579A1 EP 2016063265 W EP2016063265 W EP 2016063265W WO 2016198579 A1 WO2016198579 A1 WO 2016198579A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
hemofilter
filtration system
flow
extracorporeal blood
Prior art date
Application number
PCT/EP2016/063265
Other languages
English (en)
Inventor
Jean-Michel Lannoy
Original Assignee
Nikkiso Europe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikkiso Europe Gmbh filed Critical Nikkiso Europe Gmbh
Publication of WO2016198579A1 publication Critical patent/WO2016198579A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3403—Regulation parameters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3403—Regulation parameters
    • A61M1/341—Regulation parameters by measuring the filtrate rate or volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/342—Adding solutions to the blood, e.g. substitution solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/342—Adding solutions to the blood, e.g. substitution solutions
    • A61M1/3424—Substitution fluid path
    • A61M1/3437—Substitution fluid path downstream of the filter, e.g. post-dilution with filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/342—Adding solutions to the blood, e.g. substitution solutions
    • A61M1/3441—Substitution rate control as a function of the ultrafiltration rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/207—Blood composition characteristics hematocrit

Definitions

  • the invention generally relates to an extracorporeal blood purification system based on hemofiltration and hemo-concentration. More specifically, the invention relates to removal, or clearance, of protein-bound molecules from blood through hemo-concentration in an hemofilter.
  • Extracorporeal blood purification has been widely used, most commonly in continuous renal replacement therapies (CRRT) to treat patients suffering loss or impairment of natural kidney functions. More recently, extracorporeal blood filtration has been adapted for more general application in plasmapheresis, the purification of blood through removal of noxious components circulating in the blood plasma.
  • plasmapheresis As a means for treating ICU patients suffering from inflammatory mediator-related diseases such as septic shock, systemic inflammatory response syndrome (SIRS), and multiple organ failure (MOF). These conditions can arise from excessive release of inflammatory mediators into the bloodstream by overstimulation of the immune system.
  • plasmapheresis as well as other CRRT has been proposed as mechanisms for removing inflammatory mediators from the bloodstream to counteract an excessive inflammatory response.
  • these technologies that exchange the full plasma or that use standard CRRT procedures never demonstrated any relevant efficacy for controlling the inflammatory answer or supporting sepsis recovery.
  • a typical hemofiltration system blood is removed from a patient through an access site, usually by insertion of a venous catheter in a limb or central vein, and pumped through an extracorporeal circuit that includes an artificial kidney or hemofilter.
  • the hemofilter includes a semi-permeable membrane, usually synthetic, with pore sizes selected to pass unwanted molecules. Hemofiltration processes are classified as either low-volume hemofiltration (LVH or LVHF) or high-volume hemofiltration (HVH or HVHF). In both processes, a hydrostatic pressure circulates blood along one surface of the filter membrane thereby creating an increase of protein concentration inside the hemofilter and pushing water and waste products across the filter membrane into a filtration fluid.
  • a sterile substitution fluid usually containing bicarbonate
  • a concentration difference is created between the blood and the substitution fluid because the blood contains a high concentration of a protein-bound mediator, while the substitution fluid is essentially mediator free. This condition promotes a break of liaison, or breakage of the bond, between mediators and protein, resulting in a higher concentration of free mediators once the two fluids (blood and substitution fluid) have combined.
  • a second hemofilter is then used to filter out these free mediators, having a smaller molecular weight than protein-bound mediators, out of the blood through the filter membrane before they can be bound back to protein.
  • the combined blood and substitution fluid is then returned to the patient through another venous access site.
  • HVH therapy the procedural principle is removal of plasma water from blood through a hemofilter, and replacement of the lost fluid by addition of substitution solution.
  • An analysis of hemofiltration therapies revealed that HVH removes different quantities of certain molecules than LVH therapies and showed that HVH improves the clearance of unwanted molecules as compared to LVH.
  • Ronco showed that HVH can be effective at removing inflammatory mediators, whereas LVH has no effect on plasma levels of inflammatory mediators.
  • C. Ronco "Pulse High-Volume Hemofiltration in Sepsis", European Renal and Genito-U nary Disease, pp. 39-45, 2006.
  • HVH has also several disadvantages.
  • HVH requires larger, more expensive hemofilters with high flux membranes that can process large volumes of fluid exchange daily.
  • HVH must be critically monitored to prevent complications, such as hypothermia.
  • Hemofiltration is thus a means to deplete the blood from unwanted molecules, however, a problem which arises during hemofiltration is that a number of unwanted molecules, such as inflammatory or apoptotic mediators are fixed and transported by proteins such as albumin. As such, these molecules cannot be sufficiently cleared from the blood, since these complexes do not pass through the hemofilter into the filtrate fluid. It was now surprisingly found that the addition of citrate to the blood flow, before it passes the hemofilter provides a solution to this problem, in that the addition of citrate results in a release of molecules bound to albumin. Therefore, these unwanted molecules become freely available in the blood flow and can be cleared by passages through the hemofilter. The addition of citrate is considered safe for the patient, because it is converted into bicarbonate in the Krebs cycle.
  • the present invention provides an extracorporeal blood filtration system for removing unwanted molecules from a flow of blood from a patient, comprising:
  • a hemofilter for raising hemoconcentration of the blood in a filtered blood flow
  • a control system to set the filtration ratio for hemoconcentration in the hemofilter to be higher than 33%; in particular higher than 33% and lower than 45%. Using these settings the blood haematocrit level outside the hemofilter can reach values over 50%.
  • said filtration ratio (in the absence of citrate addition) is calculated by: 100% x (filtration flow rate / blood flow rate). If citrate is added to the blood flow, the filtration ratio is calculated by: 100% x [filtration flow rate / (blood flow rate + citrate flow rate)].
  • the filtration flow rate representing the flow rate of filtered fluid through the hemofilter.
  • the blood flow rate representing the flow rate of blood (optionally in combination with the flow rate of citrate added to the blood flow) entering the filtration system.
  • the hemofilter of said extracorporeal blood filtration system includes a semi-permeable membrane having pore sizes selected to pass the free unwanted molecules.
  • said unwanted molecules include one or more mediators.
  • these one or more mediators are inflammatory mediators.
  • the extracorporeal blood filtration system comprises a blood haematocrit sensor. Said haematocrit sensor can regulate the blood flow (with optionally the citrate flow rate) or the filtration flow rate in order to reach the determined filtration ratio (higher than 33% and lower than 45%).
  • the extracorporeal blood filtration system comprises a continuous pH sensor that adjusts the blood flow or the filtration flow rate if a pH below 7.2 is measured in the blood after the blood flow has passed through the hemofilter.
  • the extracorporeal blood filtration system comprises a means for adjusting blood flow through the hemofilter.
  • the extracorporeal blood filtration system comprises a controller for optimizing a removal rate of the unwanted molecules from the blood flow.
  • said controller adjusts one or more of blood flow in the hemofilter, transmembrane pressure in the hemofilter, flow of the substitution fluid, and pressure drop across the hemofilter.
  • the present invention comprises an extracorporeal blood filtration system as described herein above wherein the first influx system controls the addition of citrate to the blood flow before the blood flow passes the hemofilter such as to reach a final citrate concentration between 2 and 6 mmol per liter of blood, preferably between 3 and 4 mmol per liter of blood..
  • the present invention comprises a method for removing unwanted molecules from a flow of blood from a patient using an extracorporeal blood filtration system as described herein above.
  • FIG. 1 Schematic representation of the pH variation in the blood circuit using an extracorporeal blood filtration system with a filtration ratio of 22% (blue) or 32% (red). pH was measured at three different locations in the blood circuit of the present invention, namely pre-filter, across the hemofilter and in the post-dilution volume. The increased filtration ratio in the hemofilter of the present invention results in a decreased pH in the blood across the hemofilter.
  • FIG. 1 Schematic representation of the concentration of free proteins, albumin and CI " in an extracorporeal blood filtration system using a filtration ratio of 22% (A) or a filtration ratio of 32% (B). Concentration of free proteins, albumin and CI " was measured at 4 different locations in the blood circuit of the system, namely pre-filter, across the hemofilter, in the post-dilution volume and in the filtration fluid (ultrafiltrate; UF).
  • A filtration ratio of 22%
  • B a filtration ratio of 32%
  • the present invention in particular aims at providing an extracorporeal blood filtration system for removing unwanted molecules from a flow of blood from a patient.
  • the present invention provides an extracorporeal blood filtration system for removing unwanted molecules from a flow of blood from a patient comprising:
  • a hemofilter for raising hemoconcentration of the blood in a filtered blood flow
  • control system to set the filtration ratio for hemoconcentration in the hemofilter to be higher than 33%; in particular higher than 33% and lower than 45%, such that the blood haematocrit level outside the hemofilter can reach values over 50%.
  • Said filtration ratio (in the absence of citrate addition) is calculated by: 100% x (filtration flow rate / blood flow rate). If citrate is added to the blood flow as anticoagulant, the filtration ratio is calculated by: 100% x [filtration flow rate / (blood flow rate + citrate flow rate)].
  • Typical for the present invention and different from blood filtration systems available in the prior art, is that the filtration ratio in the hemofilter of the system is set higher than 33% and lower than 45%. In contrast to the presently available filtration systems, which are set to operate at a filtration ratio below 30%, the filtration ratio of the system of the present invention is largely increased, in particular higher than 33% and lower than 45%. Due to this increased filtration ratio, hemoconcentration of the blood at the hemofilter is increased.
  • said citrate is added to the blood in a concentration to reach a final citrate concentration between 2 and 6 mmol of citrate per liter of blood before the blood flow passes the hemofilter, more preferably between 3 and 4 mmol of citrate per liter of bloods.
  • the extracorporeal blood filtration system according to the present invention comprises a hemofilter for raising the hemoconcentration of the blood in a filtered blood flow and a substitution fluid for supplementing the filtered blood flow for return to the patient.
  • Typical for the present invention is that the filtration ratio for hemoconcentration in the hemofilter is set higher than 33% and lower than 45%. This high filtration ratio results in an increased hemoconcentration of the blood.
  • citrate and its anticoagulation effect plays an additional beneficial effect in the albumin detoxification since also citrate reduces the pH of the blood before the blood is filter through the hemofilter. Therefore, despite the possibility of using a standard anticoagulation procedure without citrate, it can be recommended to use citrate as anticoagulation procedure in order to catalyse the albumin detoxification objectives.
  • transporter proteins such as albumin
  • mediators such as inflammatory cytokines or standard molecules (for example calcium)
  • electronegative charge across the hemofilter. Since these negatively charged transporter proteins are unable to cross the semi-permeable membrane of the hemofilter due to their high molecular weight, other negatively charged molecules with a lower molecular weight, such as chloride ions (CI " ) will cross the semi-permeable membrane of the hemofilter, based on the Gibbs-Donnan effect.
  • CI " chloride ions
  • the difference between the CI " concentration in the filtrate fluid (ultrafluid) and the CI " concentration across the filter can be used as a marker for filtration efficiency in the extracorporeal blood filtration system according to the present invention.
  • the use of a filtration ratio of 32% markedly decreases the CI " concentration across the hemofilter, as compared to the use of a filtration ratio of 22%.
  • ACI " is increased when using a filtration ratio of 32% as compared to the use of a filtration ratio of 22%.
  • the extracorporeal blood filtration system is particularly useful for removing unwanted molecules from a flow of blood from a patient, for example intensive care unit (ICU) patients suffering from inflammatory mediator-related diseases such as septic shock, systemic inflammatory response syndrome (SIRS), and multiple organ failure (MOF). These conditions can arise from excessive release of inflammatory mediators into the bloodstream by overstimulation of the immune system. Sepsis, for example, is characterized by a complex systemic inflammatory response to a microbial pathogen.
  • ICU intensive care unit
  • SIRS systemic inflammatory response syndrome
  • MOF multiple organ failure
  • the presence of microorganisms in the bloodstream causes an innate immune response characterized by the stimulation of monocytes and release of proinflammatory cytokines and the activation of a medley of different immune pathways.
  • Conventional therapy such as antibiotics and surgical procedures to remove the source of infection is crucial for treating sepsis, but these approaches cannot reverse the effects of the bacterial toxins already release into the blood or of the endogenous inflammatory mediators produced by the host in response to bacteria.
  • Blood purification techniques including hemoperfusion, plasma exchange, and hemofiltration with hemoperfusion are associated with lower mortality in patients with sepsis.
  • Devices to remove endotoxin or inflammatory cytokines have been designed as a strategy to reduce the morbidity and mortality associated with sepsis.
  • the extracorporeal blood filtration system according to the present invention is therefore particularly useful for the treatment of patients suffering septic shock, thereby improving their survival.
  • the extracorporeal blood filtration comprises a hemofilter that includes a semi-permeable membrane having pore sizes to pass the free unwanted molecules.
  • the high filtration ratio applied in the extracorporeal blood filtration system according to the present invention results in increased hemoconcentration leading to a pH decrease in the blood flow.
  • unwanted molecules are liberated from their protein transporters.
  • the semi-permeable membrane may be selected for a membrane pore size that passes unwanted inflammatory or apoptotic mediators and that also removes calcium ions that are liberated from albumin as well.
  • the unwanted molecules include one or more mediators, in particular inflammatory mediators.
  • the extracorporeal blood filtration system comprises a haematocrit sensor for monitoring the blood haematocrit level in the blood flow outside the hemofilter.
  • Said haematocrit sensor can regulate the blood flow (with optionally the citrate flow rate) if filtration flow rate is fixed, or said haematocrit sensor can regulate the filtration flow rate if the blood flow rate is fixed. This enables to reach a determined filtration ratio higher than 33% in the extracorporeal blood filtration system according to the present invention.
  • the extracorporeal blood filtration system comprises a continuous pH sensor for monitoring the pH in the blood flow.
  • Said continuous pH sensor adjusts the blood flow or filtration rate if a pH below 7.2 is measured in the blood after the blood flow has passed through the hemofilter.
  • the continuous pH sensor decreases the blood flow or increases the filtration flow rate if a pH below 7.2 is measured in the blood after the blood flow has passed through the hemofilter.
  • the extracorporeal blood filtration system comprises a Ca 2+ sensor. Since, Ca 2+ ions are captured by albumin, they are also released from the albumin under the influence of the addition of citrate. Therefore, measurement of Ca 2+ ions can assist in the monitoring of the hemofiltration efficiency and may thus be used to assist in (automatically) adjusting citrate influx by the device.
  • the extracorporeal blood filtration system comprises one or more chloride sensors. In a particular embodiment of the present invention, the system comprises a chloride sensor for measuring chloride concentration in the blood flow. In another particular embodiment, the present invention comprises a second chloride sensor for measuring chloride concentration in the filtrate fluid.
  • the present invention comprises a chloride sensor for measuring chloride concentration in the blood flow, and another chloride sensor for measuring chloride concentration in the filtrate fluid.
  • the values measured by the two chloride sensors allow the calculation of ⁇ that serves as a marker for therapy efficiency.
  • the extracorporeal blood filtration system comprises means to determine the ⁇ over the hemofilter, such as for example by means of a chloride sensor for measuring chloride concentration in the blood flow, and another chloride sensor for measuring chloride concentration in the filtrate fluid.
  • the ACI over the hemofilter can be used as a parameter to adjust the filtration ratio for hemoconcentration in the hemofilter.
  • said ACI can be used as a marker for the detoxification of albumin across a semipermeable filter. It is thus an objective of the present invention to provide the use of ACI as a marker for the detoxification of albumin across a semi-permeable filter.
  • the extracorporeal blood filtration system comprises a means for adjusting blood flow through the hemofilter.
  • the patient access site of the extracorporeal blood filtration system may represent one or more intravenous catheters, PICC lines or central venous catheters or equivalent means for penetrating a blood vessel of the patient to draw a flow of unfiltered blood in the circuit of the extracorporeal blood filtration system.
  • a sensor which may be a blood flow detector or blood pressure sensor, may be provided to measure the flow or pressure of blood leaving the patient at the patient access site.
  • the sensor may be any commercial detector known in the art and commonly used for this purpose, such as a noninvasive infrared or ultrasonic Doppler type detector.
  • the sensor may be a pressure sensor for detecting a differential pressure between two points in the blood flow, for derivation of a signal representative of the blood flow.
  • additional sensors may be located at various points in the circuit.
  • the sensors will be disclosed as pressure sensors, although it should be appreciated that flow sensors may also be employed.
  • the present invention may also comprise a blood pump providing the mechanical force to sustain a continuous flow of blood.
  • the blood pump may be any conventional pump known in the medical field and suitable for the purpose. It should be understood that the blood pump, as well as other pumps described herein or otherwise used in different embodiments of the invention, may be conventional diaphragm, centrifugal, or peristaltic pumps typically used in the medical field. ln another embodiment, the extracorporeal blood filtration system may also comprise a means for adjusting transmembrane pressure in the hemofilter.
  • a pre-filter sensor may be installed to measure pressure in blood flow upstream of the hemofilter.
  • the hemofilter may be of conventional design and selected from commercial stock, and may include two flow paths separated from each other by a semi-permeable membrane.
  • the semi-permeable membrane may be selected for its particular pore size, i.e. its ability to pass molecules up to a certain atomic weight.
  • a filtrate pump may be installed to draw filtrate fluid from the hemofilter along one flow path as a filtrate flow.
  • a sensor may be located in filtrate flow to measure the pressure in that line. The filtrate in flow may be collected in a filtrate collector, and may ultimately be disposed of as a waste product.
  • a blood leak detector may also be installed in the filtrate flow path to detect excessive presence of blood plasma.
  • the extracorporeal blood filtration system also comprises a substitution fluid for supplementing the filtered blood flow for return to the patient.
  • This substitution fluid (also called 'post-dilution volume') is provided to add to the blood flow to compensate for volume lost as filtrate flow.
  • the substitution fluid may be any sterile intravenous fluid having a desired concentration of electrolytes, such as a dialysate solution commonly known in the art.
  • the substitution fluid may be formulated as a buffer to maintain a desired acid-base balance.
  • the substitution fluid may be an acetate-based, lactate-based, citrate-based or bicarbonate-based buffer.
  • a substitution fluid pump may be installed to force the substitution fluid to combine with the blood flow.
  • a heater may be installed in the flow path of the substitution fluid to maintain proper temperature levels and prevent hypothermia.
  • a temperature sensor may also be installed to sense and transmit an analogue or digital signal representing substitution fluid temperature to a controller to effect temperature control.
  • a pressure sensor may be located in the circuit at this point where the blood flow is combined with the substitution fluid. This pressure sensor is placed for pressure or flow measurements.
  • an air bubble trap, an air bubble detector, and/or an automatic clamp may be installed in the circuit as safety precautions at points upstream of a patient blood return site. The air bubble trap may be placed into the blood flow for removal of unwanted micro bubbles.
  • the air bubble detector may be placed into the blood flow downstream of all pumps in the circuit, to detect the undesirable presence of air bubbles or air gaps in blood flow. Any air bubble detector known in the medical field, such as ones operating on ultrasonic or infrared sensing technology may be used for this purpose.
  • the automatic clamp may be placed between the air bubble detector and a patient blood return site. In one embodiment, a solenoid valve may be employed as the automatic clamp. In another embodiment, the air bubble detector and the automatic clamp interface electronically with a controller.
  • the return site may be provided using an appropriate and complimentary catherization method as used for the access site.
  • the extracorporeal blood filtration system comprises a controller for optimizing a removal rate of the unwanted molecules from the blood flow.
  • this controller adjusts one or more of blood flow in the hemofilter, transmembrane pressure in the hemofilter, flow of the substitution fluid, and pressure drop across the hemofilter.
  • a central computer or controller may allow a user to manually or automatically control components within the hemofiltration circuit.
  • the components may include the blood pump, the filtrate pump, substitution fluid pump, the substitution fluid heater and the automatic clamp.
  • Control loops may be enabled by the controller that communicates with and/or receives sensoring input from various instrumentation within the hemofiltration circuit.
  • the present invention comprises a method for removing unwanted molecules from a flow of blood from a patient using an extracorporeal blood filtration system as described herein above. It is accordingly an objective of the present invention to provide a method of treating patients suffering from inflammatory mediator-related diseases such as septic shock, systemic inflammatory response syndrome (SIRS), and multiple organ failure (MOF), said method comprising:
  • filtration ratio for hemoconcentration in the hemofilter is higher than 33%; in particular higher than 33% and lower than 45%;
  • substitution fluid also called 'post-dilution volume'
  • said citrate is added in a concentration to reach a final citrate concentration between 2 and 6 mmol per liter of blood, preferably between 3 and 4 mmol per liter of blood, wherein the citrate is added to the blood flow before the blood flow passes the hemofilter.

Abstract

La présente invention concerne d'une manière générale un système extracorporel d'épuration du sang qui repose sur l'hémofiltration et l'hémoconcentration. Plus spécifiquement, l'invention concerne un système extracorporel de filtration du sang destiné à éliminer les molécules indésirables présentes dans un écoulement de sang provenant d'un patient. De plus, la présente invention concerne également un procédé permettant d'éliminer les molécules indésirables d'un écoulement de sang provenant d'un patient, au moyen dudit système extracorporel de filtration du sang.
PCT/EP2016/063265 2015-06-10 2016-06-10 Système d'épuration du sang reposant sur l'hémoconcentration WO2016198579A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15171305 2015-06-10
EP15171305.4 2015-06-10
EP16152868.2 2016-01-27
EP16152868 2016-01-27

Publications (1)

Publication Number Publication Date
WO2016198579A1 true WO2016198579A1 (fr) 2016-12-15

Family

ID=56411580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/063265 WO2016198579A1 (fr) 2015-06-10 2016-06-10 Système d'épuration du sang reposant sur l'hémoconcentration

Country Status (1)

Country Link
WO (1) WO2016198579A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10345175B2 (en) 2011-05-31 2019-07-09 Nxstage Medical, Inc. Pressure measurement devices, methods, and systems
US10864312B2 (en) 2005-11-09 2020-12-15 B. Braun Medical Inc. Diaphragm pressure pod for medical fluids
WO2022086623A1 (fr) * 2020-10-23 2022-04-28 Fenwal, Inc. Collecte de plasma à programmation à distance

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0027470B1 (fr) * 1979-04-30 1984-08-01 LICHTENSTEIN, Eric S. Systeme de soins medicaux controles par ordinateur
WO2005107833A1 (fr) * 2004-05-07 2005-11-17 Gambro Lundia Ab Equipement de traitement du sang, procede et programme logiciel permettant de commander une perfusion
WO2006011009A2 (fr) * 2004-07-23 2006-02-02 Gambro Lundia Ab Machine et procedure de traitement extracorporel du sang
US20080015487A1 (en) * 2006-02-22 2008-01-17 Henry Ford Health System System and Method for Delivery of Regional Citrate Anticoagulation to Extracorporeal Blood Circuits
WO2009073567A1 (fr) * 2007-11-29 2009-06-11 Xcorporeal. Inc. Système et procédé pour réaliser une hémodialyse et une hémofiltration

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0027470B1 (fr) * 1979-04-30 1984-08-01 LICHTENSTEIN, Eric S. Systeme de soins medicaux controles par ordinateur
WO2005107833A1 (fr) * 2004-05-07 2005-11-17 Gambro Lundia Ab Equipement de traitement du sang, procede et programme logiciel permettant de commander une perfusion
WO2006011009A2 (fr) * 2004-07-23 2006-02-02 Gambro Lundia Ab Machine et procedure de traitement extracorporel du sang
US20080015487A1 (en) * 2006-02-22 2008-01-17 Henry Ford Health System System and Method for Delivery of Regional Citrate Anticoagulation to Extracorporeal Blood Circuits
WO2009073567A1 (fr) * 2007-11-29 2009-06-11 Xcorporeal. Inc. Système et procédé pour réaliser une hémodialyse et une hémofiltration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. RONCO: "Pulse High-Volume Hemofiltration in Sepsis", EUROPEAN RENAL AND GENITO-URINARY DISEASE, 2006, pages 39 - 45
LEE JUNG CHAN ET AL: "Mathematical analysis for internal filtration of convection-enhanced high-flux hemodialyzer.", COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, vol. 108, no. 1, October 2012 (2012-10-01), pages 68 - 79, XP002746544, ISSN: 1872-7565 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10864312B2 (en) 2005-11-09 2020-12-15 B. Braun Medical Inc. Diaphragm pressure pod for medical fluids
US10345175B2 (en) 2011-05-31 2019-07-09 Nxstage Medical, Inc. Pressure measurement devices, methods, and systems
US11529448B2 (en) 2011-05-31 2022-12-20 Nxstage Medical, Inc. Pressure measurement devices, methods, and systems
WO2022086623A1 (fr) * 2020-10-23 2022-04-28 Fenwal, Inc. Collecte de plasma à programmation à distance

Similar Documents

Publication Publication Date Title
AU2013362119B2 (en) Haemodiafiltration method
EP0951303B1 (fr) Dispositif de preparation d'une solution de substitution
CA2724060C (fr) Appareil d'hemodialyse ou d'hemo(dia)filtration et procede de controle d'un appareil d'hemodialyse ou d'hemo(dia)filtration
JP5543049B2 (ja) 血液浄化装置の作動方法及び血液浄化装置
Bellomo et al. Nomenclature for continuous renal replacement therapies
US8795218B2 (en) Method of removing unwanted molecules from blood
US20030236482A1 (en) Apparatus and method for in-vivo plasmapheresis using periodic backflush
US9814822B2 (en) Plasma generation with dialysis systems
Honore et al. What a clinician should know about a renal replacement membrane?
US10322220B2 (en) Method and device for extracorporeal blood treatment
WO2016198579A1 (fr) Système d'épuration du sang reposant sur l'hémoconcentration
Azar et al. Hemodialysis system
Zaccaria et al. Principles of Extracorporeal Circulation and Transport Phenomena
Kox et al. Practical aspects of renal replacement therapy
Golper et al. Continuous venovenous hemofiltration for acute renal failure in the intensive care setting: Technical considerations
Vanholder et al. Single needle haemodialysis
Benz et al. Technical Aspects of hemodialysis in Children
US20170021075A1 (en) Mid-dilution hemodiafiltration with multi-line dialysate supply
Schaefer et al. Technical Aspects of Hemodialysis in Children
Ronco et al. Nomenclature for continuous renal replacement therapies
González-Fernández et al. PROTOCOL OF EXTRACORPOREAL PURIFICATION TECHNIQUES
Benz et al. Technical 17 in Children
Ronco et al. The extra-corporeal circuit: physical principles and monitoring
Lysaght et al. Mass transfer in arteriovenous hemofiltration
Ahmad Hemodialysis technique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16738681

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16738681

Country of ref document: EP

Kind code of ref document: A1